ClinicalTrials.gg
RecruitingNCT07204756Updated Jan 14, 2026

HOPE-BP 2.0: Evaluating the Optimal Duration of Postpartum Remote Blood Pressure Monitoring

An interventional study of 2-Week Home Monitoring and 6-Week Home Monitoring in Postpartum, Hypertension and Hypertensive Disorder of Pregnancy, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by University of Minnesota · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 23 studies in Hypertension by University of Minnesota — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · University of Minnesota.

Planned enrollment
2nd of 15
400 · median 79
Started
2026
the only one that year
No phase
8 of 23
2 open now
Registered
22nd of 23
by date

Among the 23 studies in Hypertension by University of Minnesota, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 8 with no phase, and was the 22nd registered.

Hypertension

6,125 studies on the registry are indexed under Hypertension; 910 are open to participants now.

Browse Hypertension studies →

Open to participants now

4 of the 23 studies in Hypertension by University of Minnesota are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 557 Hypertension studies recruiting now, 264 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 138 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hypertension by University of Minnesota, or all of them as a file.
02

Study summary

Postpartum remote blood pressure monitoring programs for patients with hypertensive disorders of pregnancy (HDP) are becoming part of standard postpartum management. Existing programs range in duration from 2 to 6 weeks but there has not been any evaluation as to what program duration is optimal. The primary objective of this study is to evaluate the impact of program duration on clinical outcomes for patients participating in a single institution's postpartum remote blood pressure monitoring program for patients with HDP.

03

Conditions studied

  • Postpartum
  • Hypertension
  • Hypertensive Disorder of Pregnancy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Discharged after delivery at University of Minnesota Medical Center
  • Enrolled into the HOPE-BP Program

Exclusion criteria

Exclusion Criteria:

  • Ongoing antihypertensive medication use at 2 weeks (time of randomization)
  • Have a medical comorbidity that would not be clinically appropriate to randomize
  • Patients opted out of clinical research
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    2-Week Arm

    Participants randomized into the 2 week arm will be immediately unenrolled from the postpartum remote blood pressure monitoring program and resume standard postpartum care

    Diagnostic Test: 2-Week Home Monitoring

  • Active comparator
    6-Week Arm

    Patients randomized into the 6 week arm will continue and complete the program in its entirety per current SOC (4 additional weeks)

    Diagnostic Test: 6-Week Home Monitoring

Interventions

  • Diagnostic test2-Week Home Monitoring

    Those who are randomized into the 2-week intervention arm will be unenrolled from the postpartum remote blood pressure monitoring program and therefore will no longer be transmitting twice daily blood pressures for review.

  • Diagnostic test6-Week Home Monitoring

    HOPE-BP provides remote monitoring for the 35% of approximately 2,800 annual births at our institution complicated by HDP. Eligible patients enroll at hospital discharge into a 6-week program, submitting blood pressure readings twice daily via Epic's MyChart Care Companion. Participants receive immediate automated feedback, and a dedicated Maternal Fetal Medicine nursing team reviews data daily (Monday-Friday, 8 AM-4 PM), initiating or adjusting antihypertensive therapy as needed.

06

What researchers measure

Primary outcomes

  1. Diastolic Blood Pressure

    The primary outcome will be the patient's diastolic blood pressure (DBP) at their 6-week postpartum visit.

    Time frame: Week 6

Secondary outcomes

  1. Systolic Blood Pressure at 6 weeks post-partum

    Patient's systolic blood pressure at their 6-week postpartum visit

    Time frame: Week 6

  2. 6-Week Post-partum Follow-up Rates

    Participants who complete a 6-week post-partum visit / Total participants eligible for a 6-week post-partum visit

    Time frame: Week 6

  3. Unscheduled OB visit, triage visit, ED visit, or readmission rates

    Time frame: Week 6

  4. Patient Satisfaction Survey responses at 6 weeks

    PSS Score, where higher score indicates greater satisfaction

    Time frame: Week 6

  5. Rate of severe hypertension

    defined as systolic blood pressure ≥ 160mmHg and/or DBP ≥ 110 mmHg

    Time frame: Week 6

  6. Rate of new hypertension diagnosis at 6 weeks postpartum

    based on American Heart Association and American College of Cardiology criteria (AHA/ACC)

    Time frame: Week 6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2028, 24 months after the start.

Of 1,406 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 24 months is close to that.

Counting every sponsor, half of 1,501 studies reached it within 23 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 2, 2025
StartActual
Jan 7, 2026
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jan 31, 2028
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07204756
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Jan 7, 2026
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Jan 14, 2026

Study contacts

Erin Linden
Contact
linde491@umn.edu
612-625-2273
Bethany Sabol, MD MAS
principal investigator · University of Minnesota

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion